Reference health
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
33/33 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
8 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 33 checked references that resolve
resolves10.1038/s41541-021-00292-w
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
resolves10.1056/NEJMoa2101765
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
resolves10.1016/S0140-6736(21)00947-8
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
resolves10.1016/S0140-6736(21)00448-7
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
resolves10.1016/S0140-6736(21)00677-2
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
resolves10.1038/s41541-021-00336-1
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
resolves10.1136/rmdopen-2021-001594
Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases
resolves10.1136/rmdopen-2020-001553
Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines
resolves10.1016/j.jbi.2019.103208
The REDCap consortium: Building an international community of software platform partners
resolves10.1016/j.jbi.2008.08.010
Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
resolves10.1136/annrheumdis-2020-218019
Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs
resolves10.1093/rheumatology/kex352
Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study
resolves10.1136/annrheumdis-2021-220231
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
resolves10.1136/annrheumdis-2021-220647
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
resolves10.1136/annrheumdis-2021-220272
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
resolves10.1136/annrheumdis-2021-220539
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
resolves10.1136/annrheumdis-2021-220461
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
resolves10.1016/S2665-9913(21)00221-6
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
resolves10.1136/annrheumdis-2021-220732
Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City
resolves10.1007/s00296-021-04972-7
Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis
resolves10.1002/acr2.11336
Incidence of Disease Flare After BNT162b2 Coronavirus Disease 2019 Vaccination in Patients With Rheumatoid Arthritis in Remission
resolves10.1007/s00296-021-04917-0
Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
resolves10.1136/annrheumdis-2021-221252
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series
resolves10.1136/annrheumdis-2021-221326
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
resolves10.55563/clinexprheumatol/xj2pqk
Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis
resolves10.1007/s00296-021-05017-9
Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study
resolves10.1038/s41591-021-01469-5
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
resolves10.1136/annrheumdis-2021-221097
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus
resolves10.3389/fimmu.2021.740249
ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
resolves10.3390/vaccines9070730
Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study
resolves10.1136/rmdopen-2021-001814
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
resolves10.1136/annrheumdis-2021-221217
SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases
resolves10.1186/s12916-021-02059-5
Evaluation of the safety profile of COVID-19 vaccines: a rapid review
The 8 references without a DOI — listed, not checked
no DOI — not checked10.1136/annrheumdis-2021-221490_bib2
no DOI — not checked10.1136/annrheumdis-2021-221490_bib3
no DOI — not checkedView points on SARS-CoV-2 vaccination in patients with RMDs
no DOI — not checkedAmerican College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3
no DOI — not checked10.1136/annrheumdis-2021-221490_bib15
no DOI — not checkedHumoral response to pfizer mRNA vaccine against SARS CoV2, in patients with autoimmune inflammatory rheumatic diseases and the impact on the rheumatic disease activity
no DOI — not checkedDisease flare and Reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination
no DOI — not checkedEvaluation of immune response and disease status in SLE patients following SARS-CoV-2 vaccination
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1136/annrheumdis-2021-221490"><img src="https://citestamp.com/citestamped/10.1136/annrheumdis-2021-221490/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1136/annrheumdis-2021-221490)